November 25, 2016 - By Adrian Mccoy
Phillip Frost; that is an insider in Opko Health Inc who is the newest to get shares in the company for which he is right now a CEO & Chairman . Phillip recently invested in 4,300 shares of the company, that are worth approx. $43,387 U.S Dollars, that is a price per share of roughly $10.1. It seems he is very active lately as in the last month, he quietly acquired additional 121,000 shares of the company, worth $1.15 million USD. The probability that this deal remains undiscovered are little owing to the big amount of cash involved. Today, Phillip Frost owns 183.53 million shares which make up about 32.89% of the company’s market capitalization. The acquisition was dated November 25, 2016 and was made public in a 4F filing filed with the Washington-based Security and Exchange Commission. The 4F filing is obtainable online here.
Insitutional Activity: The institutional sentiment increased to 1.8 in 2016 Q2. Its up 0.80, from 1 in 2016Q1. The ratio is positive, as 33 funds sold all Opko Health Inc. shares owned while 63 reduced positions. 22 funds bought stakes while 74 increased positions. They now own 102.34 million shares or 2.14% more from 100.19 million shares in 2016Q1.
Goldman Sachs Group Inc Incorporated, a New York-based fund reported 2.00 million shares. Moreover, First Allied Advisory has 0.02% invested in Opko Health Inc. (NASDAQ:OPK) for 43,489 shares. Moreover, Mycio Wealth Prtn Limited Liability Co has 0% invested in Opko Health Inc. (NASDAQ:OPK) for 597 shares. Clal Insur Enterprises Ltd holds 2.25 million shares or 0.54% of its portfolio. Qs Invsts Ltd Llc accumulated 0% or 34 shares. Cubist Systematic Strategies Ltd holds 0.01% of its portfolio in Opko Health Inc. (NASDAQ:OPK) for 20,521 shares. State Common Retirement Fund accumulated 765,119 shares or 0.01% of the stock. The Connecticut-based Fairfield Bush And has invested 0.33% in Opko Health Inc. (NASDAQ:OPK). The Hong Kong-based Point72 Asia (Hong Kong) Ltd has invested 0.02% in Opko Health Inc. (NASDAQ:OPK). Amici Capital Limited Company accumulated 81,000 shares or 0.14% of the stock. Northern Trust Corp last reported 0% of its portfolio in the stock. Geode Capital Management Limited Liability Com accumulated 2.19M shares or 0.01% of the stock. Blackrock Advsr Ltd Limited Liability Company has 0.01% invested in the company for 817,637 shares. Benjamin F Edwards & Incorporated holds 0% or 1,250 shares in its portfolio. Oracle Mgmt has invested 8.51% of its portfolio in Opko Health Inc. (NASDAQ:OPK).
Insider Transactions: Since May 26, 2016, the stock had 64 buys, and 0 selling transactions for $5.67 million net activity. $18,692 worth of shares were bought by FROST PHILLIP MD ET AL on Friday, November 18.
The stock increased 4.90% or $0.5 on November 23, hitting $10.7. Opko Health Inc. (NASDAQ:OPK) has declined 4.89% since April 22, 2016 and is downtrending. It has underperformed by 10.30% the S&P500.
OPKO Health, Inc. is a healthcare company. The company has a market cap of $6.26 billion. The Firm operates through two divisions: diagnostics and pharmaceutical. It currently has negative earnings. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations.
According to Zacks Investment Research, “OPKO Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.”
Analysts await Opko Health Inc. (NASDAQ:OPK) to report earnings on March, 6. After $-0.03 actual earnings per share reported by Opko Health Inc. for the previous quarter, Wall Street now forecasts 66.67% negative EPS growth.
OPKO Health, Inc. (OPKO), incorporated on November 18, 1991, is a healthcare company. The Firm operates through two divisions: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical activities in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The Company’s pharmaceutical business features Rayaldee, a treatment for secondary hyperparathyroidism (SHPT) in patients with stage III or IV chronic kidney disease (CKD) and vitamin D insufficiency and VARUBI for chemotherapy-induced nausea and vomiting. The Company’s pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico. The Firm has a development and commercial supply pharmaceutical company, as well as a global supply chain operation and holding firm in Ireland. It also owns a specialty active pharmaceutical ingredients (APIs) maker in Israel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy